DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells

CNS Neuroscience and Therapeutics

Volumn 21, Issue 7, 2015, Pages 549-557

  Kornelius, Edy ^a,b   Lin, Chih Li ^a,b   Chang, Hsiu Han ^b   Li, Hsin Hua ^b   Huang, Wen Nung ^b   Yang, Yi Sun ^a,b   Lu, Ying Li ^a,b   Peng, Chiung Huei ^c   Huang, Chien Ning ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; AMP activated protein kinase; Amyloid ; Linagliptin; Sirtuin 1

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LINAGLIPTIN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TAU PROTEIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AMYLOID BETA-PROTEIN (1-42); CHROMONE DERIVATIVE; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MORPHOLINE DERIVATIVE; PEPTIDE FRAGMENT; SIRT1 PROTEIN, HUMAN; SOMATOMEDIN C; SUPEROXIDE DISMUTASE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGED; ALZHEIMER DISEASE; CELL SURVIVAL; COMPLICATION; DIABETES MELLITUS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMP-ACTIVATED PROTEIN KINASES; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCAGON-LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LINAGLIPTIN; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MORPHOLINES; NEUROBLASTOMA; PEPTIDE FRAGMENTS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIRTUIN 1; SUPEROXIDE DISMUTASE;

EID: 84931562584     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12404     Document Type: Article

References (44)

1. Spielman LJ, Little JP, Klegeris A. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J Neuroimmunol 2014;273:8-21.
2. de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 2014;88:548-559.
3. Zemva J, Schubert M. Central insulin and insulin-like growth factor-1 signaling: Implications for diabetes associated dementia. Curr Diabetes Rev 2011;7:356-366.
4. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014;63:2232-2243.
5. Butterfield DA, Swomley AM, Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid Redox Signal 2013;19:823-835.
6. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer's disease: Molecular links & clinical implications. Curr Alzheimer Res 2008;5:438-447.
7. Rulifson EJ, Kim SK, Nusse R. Ablation of insulin-producing neurons in flies: Growth and diabetic phenotypes. Science 2002;296:1118-1120.
8. Heras-Sandoval D, Ferrera P, Arias C. Amyloid-beta protein modulates insulin signaling in presynaptic terminals. Neurochem Res 2012;37:1879-1885.
9. Bhat NR, Thirumangalakudi L. Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis 2013;36:781-789.
10. Tokutake T, Kasuga K, Yajima R, et al. Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J Biol Chem 2012;287:35222-35233.
11. Quintanilla RA, Dolan PJ, Jin YN, Johnson GV. Truncated tau and Abeta cooperatively impair mitochondria in primary neurons. Neurobiol Aging 2012;33:619 e25-619 e35.
12. Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease. Discov Med 2013;16:277-286.
13. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
14. Grigoropoulou P, Eleftheriadou I, Zoupas C, Diamanti-Kandarakis E, Tentolouris N. Incretin-based therapies for type 2 diabetes mellitus: Effects on insulin resistance. Curr Diabetes Rev 2013;9:412-417.
15. Deeks ED. Linagliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs 2012;72:1793-1824.
16. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010;5:109-117.
17. Holscher C. Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014;221:T31-T41.
18. Xiong H, Zheng C, Wang J, et al. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J Alzheimers Dis 2013;37:623-635.
19. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012;26:871-882.
20. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-182.
21. Kern M, Kloting N, Niessen HG, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012;7:e38744.
22. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006;97:105-115.
23. Kosaraju J, Gali CC, Khatwal RB, et al. Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 2013;72:291-300.
24. Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: A possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 2013;14:22933-22966.
25. Pinho CM, Teixeira PF, Glaser E. Mitochondrial import and degradation of amyloid-beta peptide. Biochim Biophys Acta 2014;1837:1069-1074.
26. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123:2764-2772.
27. Furuya TK, da Silva PN, Payao SL, et al. SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer's Disease. Neurochem Int 2012;61:973-975.
28. de Kreutzenberg SV, Ceolotto G, Papparella I, et al. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: Potential biochemical mechanisms. Diabetes 2010;59:1006-1015.
29. Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimer's disease: The confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 2013;35:152-160.
30. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80.
31. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: More than just a peripheral hormone. J Aging Res 2012;2012:384017.
32. Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 2011;89:481-489.
33. Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers Dement 2014;10:S12-S25.
34. De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014;63:2262-2272.
35. Corbi G, Conti V, Russomanno G, et al. Adrenergic signaling and oxidative stress: A role for sirtuins? Front Physiol 2013;4:324.
36. Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim Biophys Acta 2014;1842:1693-1706.
37. Balteau M, Van Steenbergen A, Timmermans AD, et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 2014;307:H1120-H1133.
38. Yamazaki S, Satoh H, Watanabe T. Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats. Endocrinology 2014;155:3288-3301.
39. Kitada M, Koya D. SIRT1 in type 2 diabetes: Mechanisms and therapeutic potential. Diabetes Metab J 2013;37:315-325.
40. Kosaraju J, Madhunapantula SV, Chinni S, et al. Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease. Behav Brain Res 2014;267:55-65.
41. Kosaraju J, Murthy V, Khatwal RB, et al. Vildagliptin: An anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J Pharm Pharmacol 2013;65:1773-1784.
42. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009;30:229-240.
43. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14.
44. Darsalia V, Ortsater H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: A comparison with glimepiride. Diabetes 2013;62:1289-1296.